Uncommon EGFR-mutant NSCLC patients had a high PD-L1 expression and CD8+ TILs and displayed a favorable response to anti-PD-1 therapy (Chen et al., 2020). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.